Cade

Median Technologies Reports Full-Year 2021 Results and Business Indicators for the First Quarter of 2022

Retrieved on: 
Thursday, April 21, 2022
Technology, Medical Devices, Other Technology, Software, Biotechnology, Other Health, Radiology, Health, Data Management, Euronext Growth, EIB, Lists of diseases, Research, Cave rescue, Diagnosis, SME, Risk, Patient, Mission statement, Intellectual property, Growth, ISIN, Solution, Artificial intelligence, Forward-looking statement, Investment, IFRS, Technology, Cade, Cancer, AMF, D, Security (finance), Cryptocurrency, Risk management, Medical imaging, Median

Robust revenue and margin growth generated by the iCRO business nevertheless helped reduce the impact of investments related to iBiopsy at the operating level.

Key Points: 
  • Robust revenue and margin growth generated by the iCRO business nevertheless helped reduce the impact of investments related to iBiopsy at the operating level.
  • It was accounted for in the balance sheet under financial instruments, and will not impact Medians cash position.
  • Median Technologies does not undertake to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq.
  • About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Median Technologies Announces Design Completion of its iBiopsy® Lung Cancer Screening End-to-end CADe/CADx Software as Medical Device (SaMD) with Outstanding Sensitivity & Specificity Performance

Retrieved on: 
Tuesday, March 22, 2022
Research, Medical Devices, FDA, Clinical Trials, Other Health, Biotechnology, Health, Science, Oncology, Other Science, National Lung Screening Trial, Cancer, Brag, Diagnosis, Medical device, CE marking, LCS, Cade, Technology, Precision medicine, CEO, Software, Lung cancer staging, ISIN, Sensitivity, NLST, NASH, Health, Artificial intelligence, Liver cancer, SME, Lists of diseases, HCC, Solution, Cave rescue, Cirrhosis, FDA, Lung cancer, Patient, DS, Data science, Prognosis, Medical imaging

Median Technologies (ALMDT:PA) announces outstanding performance of its iBiopsy LCS AI/ML tech-based end-to-end CADe/CADx Software as Medical Device, intended to enable early detection and characterization of lung cancer nodules and improve clinical management of patients.

Key Points: 
  • Median Technologies (ALMDT:PA) announces outstanding performance of its iBiopsy LCS AI/ML tech-based end-to-end CADe/CADx Software as Medical Device, intended to enable early detection and characterization of lung cancer nodules and improve clinical management of patients.
  • With this breakthrough innovation, Medians iBiopsy LCS SaMD brings a unique AI-powered solution for clinicians to fight lung cancer, the deadliest cancer worldwide.
  • Results released today show unrivalled performance for Medians end-to-end detection/diagnosis approach for lung cancer screening.
  • These results pave the way for a disruptive approach in lung cancer screening management, Fredrik Brag, CEO and founder of Median Technologies said.

FDA Clears World’s First AI Software to Read Dental X-Rays

Retrieved on: 
Tuesday, March 8, 2022
Health, FDA, Technology, Other Technology, Software, Dental, Radiology, US FDA, Dentistry, Patient, X-ray, Crown, Data, Software, Cade, Craft Ventures, Chief Dental Officer (Canada), Calculus, FDA, Solution, DMD, Efficiency, Second, Time, Communication, CEO, Review, AI, Technology, Radioactive decay, Dental care, Algorithm, Dentist, Medical device, Pearl, Health

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    Pearls announcement marks an important step forward for technology-assisted dental care.
  • We endeavor to establish a standard of care through instruction at dental school, but at some point our instruction stops.
  • Pearl's AI driven software is already in daily use by radiograph manufacturers, dentists and dental service organizations across Europe, Canada, Australiasia, South America and the Middle East.
  • Pearl is shaping the future of dental care by delivering AI and computer vision solutions that advance efficiency, accuracy, transparency and patient care.

Median Technologies Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Retrieved on: 
Thursday, March 3, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, Diagnosis, Medical device, BPI, Adoption, Patient, HCC, Liver cancer, De novo synthesis, LCS, Cirrhosis, Cade, Lists of diseases, Prognosis, Cave rescue, FDA, Solution, Precision medicine, Artificial intelligence, Calendar, Cancer, Technology, SME, Lung cancer screening, NASH, CEO, Data science, De novo, AI, Lung cancer, Classification, Software, DS, Medical imaging

Median Technologies (ALMDT) announces today that the company has filed a 513(g) submission on Feb. 17, 2022 to the United States Food and Drug Administration (FDA) for its iBiopsy Lung Cancer Screening (LCS) AI/ML technology-based end-to-end CADe/CADx1 Software as Medical Device (SaMD).

Key Points: 
  • Median Technologies (ALMDT) announces today that the company has filed a 513(g) submission on Feb. 17, 2022 to the United States Food and Drug Administration (FDA) for its iBiopsy Lung Cancer Screening (LCS) AI/ML technology-based end-to-end CADe/CADx1 Software as Medical Device (SaMD).
  • The 513(g) submission will allow Median Technologies to determine the best product classification and choose between the De Novo or the 510(k) regulatory pathways for iBiopsy LCS CADe/CADx SaMD.
  • Lung cancer is the deadliest cancer, and being able to detect it very early is of critical importance for patients.
  • About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Median Technologies Announces 2021 Revenue of €20.5 Million, Up 52%, and a Strengthened Cash Position of €39 Million

Retrieved on: 
Monday, January 17, 2022
Oncology, Medical Devices, Health, Other Health, Pharmaceutical, Biotechnology, Patient, Cade, Cave rescue, Technology, NMPA, Ginkgo CADx, Exercise, Lung cancer screening, CEO, BPI, Solution, Software, Cancer, SME, Malignancy, Lung cancer, Medical device, CT, Artificial intelligence, Diagnosis, Lists of diseases, LCS, FDA, Mission statement, Animal, Medical imaging

As of December 31, 2021, Median Technologies revenue was 20.5 million, a 52% increase compared to 2020 revenue.

Key Points: 
  • As of December 31, 2021, Median Technologies revenue was 20.5 million, a 52% increase compared to 2020 revenue.
  • The company recorded 5.1 million in revenue in Q4 2021, a 24.4% increase compared to Q4 revenue in 2020 (4.1 million).
  • As of December 31, 2021, cash and cash equivalents were 39 million, compared to 16 million as of December 31, 2020.
  • About Median Technologies: About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Median Technologies Announces Outstanding Lung Nodule Detection (CADe1) Performance for iBiopsy® Lung Cancer Screening

Retrieved on: 
Wednesday, January 5, 2022
Oncology, Medical Devices, Health, Other Health, Pharmaceutical, Biotechnology, Time, NASH, Radiology, CT, AI, Lung, Attention, Euronext Growth, Review, Software, Patient, HCC, Ginkgo CADx, Technology, Lung cancer, Cancer, Lung cancer screening, Prognosis, Artificial intelligence, Algorithm, Data science, Disease, CEO, Biomarker, Precision medicine, SME, FDA, Cade, Diagnosis, Liver cancer, Mortality, DS, LCS, Solution, Liver disease, Fatigue, Malignancy, BPI, Medical imaging

Median Technologies (ALMDT:PA) announces outstanding performance for its iBiopsy Lung Cancer Screening (LCS) CADe algorithm in detecting potentially cancerous lung nodules.

Key Points: 
  • Median Technologies (ALMDT:PA) announces outstanding performance for its iBiopsy Lung Cancer Screening (LCS) CADe algorithm in detecting potentially cancerous lung nodules.
  • When screening for lung cancer, the entire lung must be scanned, which can generate hundreds of images for each patient to detect very small lung nodules.
  • The results released today by Median Technologies specifically focus on the lung nodule detection function, which applies Medians proprietary deep learning algorithms to low-dose computed tomography (LDCT).
  • About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Samsung’s Push to Leverage Artificial Intelligence on Display at RSNA 2021

Retrieved on: 
Monday, November 29, 2021
Electronic Design Automation, Health, Medical Devices, Technology, Mobile, Wireless, Radiology, Biotechnology, Photon, Uterus, AI, Electronics, Diagnosis, Digital radiography, Ultrasound, Marketing, Artificial intelligence, Food and Drug Administration, ACCE, Food, Cade, Booth, LSI, Patient satisfaction, RSNA, Health, Memory, Workflow, Steven Novella, Massachusetts General Hospital, Apple Inc. v. Samsung Electronics Co., Samsung Electronics, Recursive neural network, Neurosurgery, PACS, Crystal, News, Samsung, LED, Solution, Anesthesiology, Critical care, ICU, Annual general meeting, Tablet, V8, Efficiency, FDA, Multimedia, Patient, Television, Radiological Society of North America, Hera, Technology, Anatomy, Radiology, PCD, Communication, Samsung Medison, Classification, Medical imaging, Medical device

View the full release here: https://www.businesswire.com/news/home/20211129005179/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211129005179/en/
    Samsung will showcase its premium diagnostic imaging solutions in ultrasound, digital radiography and mobile computed tomography at the Radiological Society of North America (RSNA) 2021 Annual Meeting.
  • We have worked to advance our solutions by leveraging high computing power and artificial intelligence (AI) technologies, said David Legg, Vice President, Digital Radiography and Ultrasound.
  • We will be deploying AI features in each of our products to provide benefits to healthcare professionals and patients alike.
  • The function is designed to provide users with accurate nerve detection, faster image processing and better workflow support.

Median Technologies Announces New Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 With a Focus on Stage 1 Lung Cancer Characterization

Retrieved on: 
Tuesday, November 23, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NSCLC, Liver cancer, AI, International Association, Diagnosis, Prognosis, Lung cancer, LCS, EIB, Cade, CEO, RSNA, Cancer, Precision medicine, Liver disease, DS, National Lung Screening Trial, NLST, European Commission Investment Plan for Europe, Death, Research, HCC, BPI, Exhibition, Euronext Growth, Committee on European Affairs and Oversight of the European Funds, Solution, Survival, Radiology, Artificial intelligence, Literature, Ginkgo CADx, FDA, SME, Patient, Adoption, Biomarker, Technology, European Investment Bank, Non-small-cell lung carcinoma, Malignancy, Data science, NASH, AUC, Disease, Medical imaging

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules.
  • New results specifically focus on the characterization of stage 1 lung cancer nodules, using Medians proprietary iBiopsy deep learning algorithm on low-dose chest computed tomography (LDCT).
  • Lung cancer is the number one cancer killer globally, causing an estimate of 1.8m deaths, accounting for 18% of all cancer deaths in 20202.
  • A noteworthy International Early Lung Cancer Action Program (I-ELCAP) cohort study of stage 1 cancer patients4 revealed an excellent 15-year LCS survival of 92% which again serves to show how critical early stage diagnosis via lung cancer screening remains.

Wision A.I. Achieves CE-MDR Mark Approval for AI-assisted Diagnostic Software Medical Device Supporting Colonoscopy

Retrieved on: 
Saturday, November 13, 2021
Mathematics, Mortality, Intelligence, RCT, Gastroenterology, ADR, Colorectal cancer, Health, Deep learning, Ownership, APC, Isabella Tree, Google Images, Large intestine, Artificial intelligence, Standard of care, MDR, Cade, SSL, Adenoma, AI, Polyp, CRC, Colonoscopy, Incidence, Veni, vidi, vici, Diagnosis, TCO, Medical Device Regulation Act, Randomized controlled trial, A.I, Patient, Death, Medical device, Silviculture, Typesetting

Ltd, a startup in the field of artificial intelligence assisted diagnostics for gastrointestinal endoscopy, today announced it received the European CE Mark approval for EndoScreener, its AI-assisted polyp detection software during colonoscopy.

Key Points: 
  • Ltd, a startup in the field of artificial intelligence assisted diagnostics for gastrointestinal endoscopy, today announced it received the European CE Mark approval for EndoScreener, its AI-assisted polyp detection software during colonoscopy.
  • It is the first CE Mark class II certificate under the new Medical Devices Regulation (MDR 2017/745).
  • Colorectal cancer (CRC) is a highly prevalent human malignancy, with over 1.9 million new cases and 935,000 deaths worldwide in 2020.
  • Lower Adenoma Miss Rate of Computer-Aided Detection-Assisted Colonoscopy vs Routine White-Light Colonoscopy in a Prospective Tandem Study.

Samsung Receives FDA Clearance for AI Algorithms that Detect Lung Nodules in Chest X-rays

Retrieved on: 
Thursday, October 28, 2021
Radiology, General Health, Health, FDA, Medical Devices, Hospitals, Technology, Other Technology, Massachusetts General Hospital, Diagnosis, Cade, Apple Inc. v. Samsung Electronics Co., Hospital, Steven Novella, Patient satisfaction, Workflow, Patient, FDA, Wangjing Nan (S) station, Food, Samsung, Severance Hospital, Samsung Medical Center, Marketing, Vuno, Samsung Digital Imaging, Multimedia, Food and Drug Administration, Artificial intelligence, Lung cancer, Solution, PACS, Digital radiography, Health, AI, Medical device, Medical imaging

NeuroLogica Corp. today announced it has received Food and Drug Administration (FDA) 510(k) clearance for its Auto Lung Nodule Detection (ALND) tool.

Key Points: 
  • NeuroLogica Corp. today announced it has received Food and Drug Administration (FDA) 510(k) clearance for its Auto Lung Nodule Detection (ALND) tool.
  • View the full release here: https://www.businesswire.com/news/home/20211028005735/en/
    Chest radiograph without Auto Lung Nodule Detection (ALND) and chest radiograph with lung nodule marked.
  • Aiding the reader's diagnosis by indicating the location of suspected lung nodules on chest X-ray images (posteroanterior chest radiographs).
  • As part of our commitment to advancing diagnostic radiology using AI, Samsung is collaborating with Vuno, a leading developer of AI solutions in healthcare.